Heterocyclic GPR52 Agonists for Potency and Solubility Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GPR52 agonists face challenges with poor aqueous solubility and high lipophilicity, limiting their application as pharmacological tools or potential drug candidates for treating psychiatric disorders and substance-use disorders.
Innovation Solution
Development of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs with improved physicochemical properties, including the introduction of nitrogen atoms in aromatic rings and strategic substitution patterns, to enhance potency and selectivity as GPR52 agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing GPR52 agonists are used, then GPR52 activation potency is achieved, but aqueous solubility is poor and lipophilicity is high
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of GPR52 agonists through strategic introduction of nitrogen atoms in aromatic rings and optimizing substitution patterns. These structural modifications alter the physicochemical parameters of the compounds, specifically improving aqueous solubility and reducing lipophilicity while maintaining or enhancing GPR52 activation potency. The systematic exploration of structure-activity relationships enables fine-tuning of these parameters to achieve the desired balance between potency and solubility.
2Reliability
If existing GPR52 agonists are used, then GPR52 activation is achieved, but selectivity is limited
Solution Approach 1:
The patent applies local quality by introducing nitrogen atoms at specific positions in aromatic rings and implementing strategic substitution patterns at particular locations on the molecular scaffold. These localized structural modifications create distinct interaction patterns with the GPR52 binding pocket, enhancing selectivity for GPR52 over other receptors. The local structural features are optimized to form specific interactions (such as hydrogen bonds or pi-stacking) that are unique to the GPR52 binding site, thereby improving target selectivity while maintaining activation potency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized compounds demonstrate nanomolar range potency, excellent target selectivity, and pharmacokinetic properties, showing antipsychotic-like activity by inhibiting amphetamine-induced hyperactivity, suggesting therapeutic potential for neuropsychiatric diseases.
Implementation Method 1
GPR52 couples to Gas/olf- G proteins to activate adenylyl cyclase and modulate 5′-cyclic adenosine monophosphate (cAMP) signaling
Implementation Method 2
GPR52 couples to Gas/olf- G proteins to activate adenylyl cyclase and modulate 5′-cyclic adenosine monophosphate (cAMP) signaling
Implementation Method 3
The agonist formed multiple interactions with GPR52 including hydrogen bonds with residues Cys40, Glu191, Ile189, Asp188 in ECL2
Implementation Method 4
π-π stacking with residue Phe300 of TM7
Implementation Method 5
hydrophobic contacts with residues Phe117, Thr303, Trp304 and Ile307
Data Source
AI summary
Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.